Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Pfizer Inc.    PFE   US7170811035

PFIZER INC. (PFE)

322
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

11/19/2012 | 09:40am US/Eastern
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
Latest news on PFIZER INC.
1h ago PFIZER : Pain Therapeutics Reports Q3 2014 Financial Results
1d ago PFIZER : Koster dismisses New York Times report that he coddles contributors
1d ago PFIZER : Interim Report January September 2014
1d ago PFIZER : PRISTIQ (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunct..
1d ago PFIZER : Receives FDA Accelerated Approval for TRUMENBA (Meningococcal Group B V..
1d ago PFIZER : U.S. approves first vaccine against dangerous meningitis strain
2d ago PFIZER : FDA approves vaccine to block meningitis strain
2d ago PFIZER : Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B ..
2d ago PFIZER : Karo Bio Interim Report January-September 2014
2d ago ZOETIS : Pfizer Announces Financial Results For Third-Quarter 2014
Advertisement
Chart
Duration : Period :
Pfizer Inc. Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF